New guidance from ADA and EASD recommends use of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for patients with type 2 diabetes

Oct 16 2018

FOR EU MEDICAL MEDIA ONLY, NOT FOR DISTRIBUTION TO US MEDIA| PDF iconDownload PDF